RBC Capital Reiterates Outperform on HOOKIPA Pharma, Maintains $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on HOOKIPA Pharma (NASDAQ:HOOK) and maintained a price target of $7.
June 30, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating on HOOKIPA Pharma and maintained a price target of $7.
The reiteration of the 'Outperform' rating by RBC Capital indicates a positive outlook for HOOKIPA Pharma. The maintained price target of $7 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100